| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/0735-1097(93)90465-D |
| P698 | PubMed publication ID | 8397233 |
| P2093 | author name string | M R Bristow | |
| P433 | issue | 4 Suppl A | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 61A-71A | |
| P577 | publication date | 1993-10-01 | |
| P1433 | published in | Journal of the American College of Cardiology | Q2984355 |
| P1476 | title | Changes in myocardial and vascular receptors in heart failure | |
| P478 | volume | 22 |
| Q41680615 | 3,5,3′ triiodo-l-thyronine pretreatment with cardioplegic arrest and chronic left ventricular dysfunction |
| Q44188991 | Age-dependent changes of cardiac neuronal noradrenaline reuptake transporter (uptake1) in the human heart |
| Q77493162 | Age-dependent decrease in the negative inotropic effect of carbachol on isolated human right atrium |
| Q34241303 | Alpha 1-adrenergic receptor regulation: basic science and clinical implications |
| Q36337283 | Altered sympathetic nervous system signaling in the diabetic heart: emerging targets for molecular imaging |
| Q38062361 | Assessment of cardiac autonomic neuronal function using PET imaging |
| Q35912365 | Assessment of cardiac sympathetic neuronal function using PET imaging |
| Q36167681 | Beta-Adrenergic blockers as antiarrhythmic and antifibrillatory compounds: an overview |
| Q30321379 | Beta-adrenergic receptors in failing human myocardium. |
| Q41252805 | Beta-blocker therapy in heart failure: myths or realities |
| Q35934078 | Biologic rationale for the use of beta-blockers in the treatment of heart failure |
| Q48347118 | Boosting the reserves: additive regulation of cardiac repolarisation |
| Q30321291 | Cardiac muscarinic receptors decrease with age. In vitro and in vivo studies. |
| Q57623287 | Cardiac positron emission tomography imaging with [11c]hydroxyephedrine, a specific tracer for sympathetic nerve endings, and its functional correlates in congestive heart failure |
| Q41031810 | Cardioprotection: definition, classification, and fundamental principles |
| Q36855013 | Carvedilol in the treatment of chronic heart failure: lessons from the Carvedilol Or Metoprolol European Trial |
| Q34166022 | Caveolin contributes to the modulation of basal and β-adrenoceptor stimulated function of the adult rat ventricular myocyte by simvastatin: a novel pleiotropic effect |
| Q33925912 | Cellular and functional defects in a mouse model of heart failure |
| Q37374337 | Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. |
| Q37358823 | Clinical and genetic modifiers of long-term survival in heart failure |
| Q40521709 | Clinical efficacy of ibopamine in patients with chronic heart failure |
| Q74530472 | Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure |
| Q82120488 | Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial |
| Q74436242 | Effects of norepinephrine on expression of IGF-1/IGF-1R and SERCA2 in rat heart |
| Q34578568 | Electrical and structural remodeling of the failing ventricle |
| Q47594909 | Electrical stimulation of the aortic depressor nerve in conscious rats overcomes the attenuation of the baroreflex in chronic heart failure. |
| Q50001572 | Electrophysiological characteristics of the rat azygos vein under electrical pacing and adrenergic stimulation. |
| Q34088198 | Evolution and pathophysiology of chronic systolic heart failure |
| Q35047149 | Functional M3 muscarinic acetylcholine receptors in mammalian hearts |
| Q47789267 | G protein-coupled receptor kinase 2 (GRK2): mechanisms of regulation and physiological functions |
| Q33923116 | Heart rate variability in the dog: is it too variable? |
| Q51015874 | Interleukin-1β induces a reversible cardiomyopathy in the mouse. |
| Q54029634 | Intravenous inotropic agents in heart failure. |
| Q45971072 | Involvement of the beta-adrenergic system in the cardiac chronic form of experimental Trypanosoma cruzi infection. |
| Q37702794 | Let-7a regulates expression of β1-adrenoceptors and forms a negative feedback circuit with the β1-adrenoceptor signaling pathway in chronic ischemic heart failure |
| Q34221055 | Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving beta-blocking agents |
| Q41669348 | Mechanism of action of beta-blocking agents in heart failure |
| Q41642167 | Mechanisms of the beneficial effects of beta-adrenoceptor antagonists in congestive heart failure. |
| Q41669341 | Molecular and cellular mechanisms of myocardial failure |
| Q37362141 | Muscarinic receptor modulation of basal and beta-adrenergic stimulated function of the failing human left ventricle |
| Q33709269 | Muscarinic receptors in the failing human heart |
| Q27315858 | Novel receptor-derived cyclopeptides to treat heart failure caused by anti-β1-adrenoceptor antibodies in a human-analogous rat model |
| Q26741100 | Novel role of phosphodiesterase inhibitors in the management of end-stage heart failure |
| Q36459142 | Pharmacogenetics of the human beta-adrenergic receptors |
| Q71528054 | Pharmacologic characterization in vitro and in vivo of iodine 123-labeled derivatives of the beta-adrenoceptor antagonist CGP12177, designed for the imaging of cardiac beta-receptors |
| Q44194519 | Potent adenylate cyclase agonist forskolin restores myoprotective effects of ischemic preconditioning in rat hearts after myocardial infarction |
| Q41679378 | Pretreatment with 3,5,3′ triiodo-l-thyronine (t3): Effects on myocyte contractile function after hypothermic cardioplegic arrest and rewarming |
| Q41024501 | Receptor regulation: why should an anesthesiologist care? |
| Q44505849 | Regulation of the cAMP-elevating effects of isoproterenol and forskolin in cardiac myocytes by treatments that cause increases in cAMP. |
| Q74315535 | Relation of tissue Doppler derived myocardial velocities to myocardial structure and beta-adrenergic receptor density in humans |
| Q44899571 | Remodeling of the chronic severely failing ischemic sheep heart after coronary microembolization: functional, energetic, structural, and cellular responses |
| Q44518214 | Repetitive preischemic infusion of phosphodiesterase III inhibitor olprinone elicits cardioprotective effects in the failing heart after myocardial infarction |
| Q48030248 | Role of G protein-coupled receptor kinase 2 and arrestins in beta-adrenergic receptor internalization |
| Q34996538 | Should beta-blockers be used for the treatment of pediatric patients with chronic heart failure? |
| Q53140898 | Sympathetic hyper-excitation in obesity and pulmonary hypertension: physiological relevance to the 'obesity paradox'. |
| Q35993913 | Sympathetic stimulation increases dispersion of repolarization in humans with myocardial infarction |
| Q38974127 | Targeting β3-Adrenergic Receptors in the Heart: Selective Agonism and β-Blockade. |
| Q97522564 | The Association of Extreme Tachycardia and Sustained Return of Spontaneous Circulation after Nontraumatic Out-of-Hospital Cardiac Arrest |
| Q38815425 | The Type 2 Diabetic Heart: Its Role in Exercise Intolerance and the Challenge to Find Effective Exercise Interventions |
| Q73862796 | The effect of salbutamol on skeletal muscle in chronic heart failure |
| Q58123133 | The potential use of AKAP18δ as a drug target in heart failure patients |
| Q36629879 | The role of adrenergic receptor polymorphisms in heart failure |
| Q37161633 | The role of the autonomic nervous system in sudden cardiac death. |
| Q34088204 | beta-blocker therapy: a standard of care for heart failure |
| Q61965183 | β-Adrenoceptor density in chronic infarcted myocardium: a subtype specific decrease of β1-adrenoceptor density |
Search more.